Increased risks of polycythemia vera (PV), essential Thrombocythemia (ET), and myelofibrosis (MF) among 24577 first-degree relatives of 11039 patients with chronic myeloproliferative disorders (MPD) in sweden.

被引：0
|
作者：
Landgren, Ola [1 ,2 ]
Goldin, Lynn R. [1 ]
Kristinsson, Sigurdur Y. [2 ]
Samuelsson, Jan [3 ]
Bjorkholm, Magnus [2 ]
机构：
[1] Natl Canc Inst, NIH, Bethesda, MD USA
[2] Karolinska Univ Hosp & Inst, Dept Med, Hematol Ctr, Stockholm, Sweden
[3] Stockholm S Hosp, Dept Med, Stockholm, Sweden
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.680.680
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
680
引用
收藏
页码：209A / 209A
页数：1
相关论文
共 19 条
  • [1] Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
    Landgren, Ola
    Goldin, Lynn R.
    Kristinsson, Sigurdur Y.
    Helgadottir, Elin A.
    Samuelsson, Jan
    Bjorkholm, Magnus
    BLOOD, 2008, 112 (06) : 2199 - 2204
  • [2] Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia Vera (PV) and chronic idiopathic myelofibrosis (CIMF)
    Michiels, J. J.
    Bernema, Z.
    Van Bockstaele, D.
    De Raeve, H.
    Schroyens, W.
    PATHOLOGIE BIOLOGIE, 2007, 55 (02): : 92 - 104
  • [3] A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Sandy, Lonette
    Lu, Min
    Yoon, James
    Petersen, Bruce
    Zhang, David
    Ye, Fei
    Newsom, Carrie
    Najfeld, Vesna
    Hochman, Tsivia
    Goldberg, Judith D.
    Hoffman, Ronald
    LEUKEMIA RESEARCH, 2017, 53 : 13 - 19
  • [4] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [5] A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Datoguia, Tarcila Santos
    Goncalves, Giulliana A. R.
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [6] Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Puga, Renato D.
    Alves Paiva, Raquel de Melo
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [7] Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Giles, Jennifer L. K.
    Pitou, Celine
    Zimmermann, Annamaria Hayden
    Price, Gregory L.
    Walgreen, Richard A.
    Prchal, Josef
    BLOOD, 2013, 122 (21)
  • [8] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [9] Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Rhoades, Susanne Kloeker
    Giles, Jennifer L. K.
    Pitou, Celine
    Jones, Emma
    Walgren, Richard A.
    Prchal, Josef T.
    BLOOD, 2011, 118 (21) : 1213 - 1214
  • [10] A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H. M.
    Pardanani, A.
    Thomas, D. A.
    Cortes, J. E.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Tefferi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12